UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of “Buy” from Brokerages

UroGen Pharma Ltd. (NASDAQ:URGN) has been assigned an average rating of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $38.20.

Several research firms have weighed in on URGN. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Monday, March 10th. HC Wainwright dropped their price objective on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price on the stock.

UroGen Pharma Price Performance

NASDAQ:URGN opened at $10.10 on Thursday. The stock has a market capitalization of $465.55 million, a PE ratio of -3.21 and a beta of 0.80. UroGen Pharma has a 1-year low of $8.97 and a 1-year high of $20.70. The firm has a fifty day simple moving average of $10.62 and a 200 day simple moving average of $11.31. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. On average, research analysts expect that UroGen Pharma will post -3.12 EPS for the current fiscal year.

Insider Buying and Selling at UroGen Pharma

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in URGN. Rhumbline Advisers grew its stake in UroGen Pharma by 4.3% in the 1st quarter. Rhumbline Advisers now owns 53,466 shares of the company’s stock valued at $591,000 after purchasing an additional 2,196 shares during the period. GAMMA Investing LLC boosted its holdings in shares of UroGen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock worth $83,000 after buying an additional 7,392 shares during the last quarter. Wellington Management Group LLP grew its position in UroGen Pharma by 7.0% during the fourth quarter. Wellington Management Group LLP now owns 146,953 shares of the company’s stock valued at $1,565,000 after buying an additional 9,653 shares during the period. Toronto Dominion Bank purchased a new stake in UroGen Pharma during the fourth quarter worth about $18,628,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in UroGen Pharma by 2.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock worth $14,667,000 after buying an additional 36,084 shares during the last quarter. 91.29% of the stock is owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.